U.S. Trustee withdraws conversion motion in Azzur Group wind-down; reports show $5.8M paid on admin claims, none to unsecured creditors
ElevenFlo ·
Azzur Group's liquidating plan has been effective since October 21, 2025, and on October 22, 2026 the U.S. Trustee withdrew its motion to compel reports and fee payments or else convert or dismiss the cases Dkt. 969. The latest post-confirmation report shows $5.84 million of administrative claims paid, nothing yet paid to general unsecured creditors and quarterly U.S. Trustee fees still not current Dkt. 968. Those payments and a final report are still to come.
Jump to section
Azzur's liquidating plan has been effective since October 21, 2025, after the sale of its three businesses for a combined $72.6 million.
On October 22, 2026, the U.S. Trustee withdrew its motion to compel the Azzur debtors to file monthly operating reports and post-confirmation reports and to pay outstanding quarterly fees, or else to convert the cases to chapter 7 or dismiss them Dkt. 969. The motion was filed on April 10, 2026. Its hearing was moved from August 13 to September 23, 2026 Dkt. 960 and then to November 19, 2026 Dkt. 963. The November 19 hearing has been cancelled.
Before the withdrawal, the debtors filed the reports the motion sought. On July 8, 2026, they filed monthly operating reports for the period ending October 3, 2025 for affiliates including Azzur Labs-Boston LLC and Cobalt LLC Dkt. 954. Between September 4 and October 21, 2026, the wind-down debtor filed post-confirmation reports for each quarter from the one ended December 31, 2025 through the one ended September 30, 2026. The latest report shows $6,973,652 disbursed since the effective date and $5,840,191 of administrative claims paid in full. Nothing has yet been paid on $1,930,000 of secured claims or $625,000 of general unsecured claims. The report is not final, and it says the debtor is not current on quarterly U.S. Trustee fees Dkt. 968. The remaining steps are paying those claims, bringing the fees current and filing a final report.
Azzur Group Holdings LLC is a Hatboro, Pennsylvania provider of GxP consulting, laboratory and on-demand cleanroom services to life sciences companies glensidelocal.com: Hatboro, Pennsylvania (outside source, not verified by ElevenFlo). It filed chapter 11 in Delaware with its affiliates on March 2, 2025 Dkt. 1. The first-day declaration traces the filing to two causes: a Cleanrooms on Demand expansion that grew faster than revenue, and covenant breaches under the company's M&T Bank loan Dkt. 12. Azzur Labs had been sold for $16 million two months before the filing. In chapter 11, Azzur Consulting went to Eliquent Life Sciences for $56 million and the cleanroom business went to Chrysalis Holdings LLC for $600,000 Dkt. 531. The court refused to confirm the debtors' plan in May 2025. It confirmed a revised liquidating plan on October 3, 2025, after insiders and equity holders agreed to add $790,000 for unsecured creditors Dkt. 736.
The wind-down has paid administrative claims in full and nothing yet to unsecured creditors
The confirmation order made Azzur Group, LLC the wind-down debtor, dissolved the other debtor entities on the effective date and set aside a $500,000 wind-down reserve. It deemed the prepetition officers and directors resigned and appointed Maria Yip of Yip Associates as Plan Administrator at $600 per hour Dkt. 736. Ilya Vasserman, identified as wind-down advisor, signed the 2026 post-confirmation reports. Those reports list 32 affiliated debtors with no activity Dkt. 967.
- $5,357,662
- $1,476,549
- $41,106
- $98,335
Show the numbers
| Quarter ended | Report filed | Disbursements |
|---|---|---|
| Dec. 31, 2025 | Sept. 4, 2026 | $5,357,662 |
| Mar. 31, 2026 | Oct. 14, 2026 | $1,476,549 |
| June 30, 2026 | Oct. 14, 2026 | $41,106 |
| Sept. 30, 2026 | Oct. 21, 2026 | $98,335 |
| Since the effective date | $6,973,652 |
In the quarter ended March 31, 2026, the wind-down debtor paid $450,553.21 to Stretto, the claims and noticing agent, under its retention order Dkt. 966. Fees paid to non-bankruptcy professionals reached $169,395 by September 30, 2026 Dkt. 968.
Through September 30, 2026, the reports carry $1,930,000 of secured claims and $625,000 of general unsecured claims, with no payment on either Dkt. 968. The $625,000 equals the general unsecured recovery that the First Amended plan estimated in May 2025. That estimate predates the Global Settlement, which added $790,000 for Class 4 Dkt. 531.
Professionals took a discount to fit the fee escrow
The reports for the first three quarters of 2026 state that approved bankruptcy professional fees and expenses for the debtors and the Committee totaled $8,866,582.25. The professional-fee escrow held $5,840,190, so the professionals agreed to accept a discounted amount Dkt. 968. The report for the quarter ended December 31, 2025 put fees approved under the final fee orders at $8,416,029 Dkt. 962.
| Professional | Role | Fees approved |
|---|---|---|
| DLA Piper LLP (US) | Debtors' counsel | $2,907,088 |
| Ankura Group Holdings, LLC | CRO and financial advisor | $2,068,846 |
| Pachulski Stang Ziehl & Jones LLP | Committee counsel | $1,697,599 |
| Brown Gibbons Lang & Co. Securities LLC | Investment banker | $1,125,144 |
| Huron Consulting Services LLC | Committee financial advisor | $566,163 |
| Stretto, Inc. | Claims and noticing agent | $36,638 |
The court resolved the fee applications in December 2025. On December 15, 2025, it entered an omnibus fee order for the debtor professionals Dkt. 771 and separate orders for Pachulski Dkt. 770 and Huron Dkt. 772. Ankura's compensation was addressed through staffing reports and the debtor-professional omnibus order. The DLA Piper fee application said its requested compensation reflected a 12.5% client accommodation Dkt. 753.
A Baird-backed cleanroom expansion outran post-pandemic demand
Azzur Group was founded in 2010 and provided full-lifecycle GxP services to pharmaceutical, biotechnology and medical device companies. It grew to 18 locations in nine states and more than 350 life science clients, served through three units. Azzur Consulting provided regulatory, compliance, quality assurance and GxP advisory services through more than 260 cGMP consultants, engineers and scientists. Azzur Labs offered analytical testing, including chemistry, microbiology and environmental monitoring. Cleanrooms on Demand provided ISO-classified cleanroom facilities to biotech and pharmaceutical clients.
In April 2021, Azzur announced an investment from Baird Capital prnewswire.com: Azzur Group announced an investment from Baird Capital (outside source, not verified by ElevenFlo), a private equity firm with pharma services expertise bairdcapital.com: expertise in pharma services (outside source, not verified by ElevenFlo). The investment was meant to speed expansion of Azzur's services, with emphasis on Cleanrooms on Demand. The capital structure chart in the first-day declaration lists equity of $76.3 million from Yotomachi, LLC, $30.2 million from Azzur Blocker, LLC and $2.3 million from other purchasers, for $108.8 million in total Dkt. 12 · p. 28. As part of the Baird transaction, Gary Knight, former Global Head of Strategy at VWR/Avantor, joined the board as an independent director. Founder and Chairman Michael Khavinson kept effective voting control through an irrevocable proxy. Brown Gibbons Lang & Company was Azzur's financial advisor on the deal.
According to the first-day declaration, the investment came at a time of high demand for pharmaceutical manufacturing capacity Dkt. 12. COVID-19 pushed testing, diagnostics and manufacturing capabilities toward capacity pharmaceuticalmanufacturer.media: pushed testing, diagnostics, and manufacturing capabilities toward capacity (outside source, not verified by ElevenFlo) and exposed shortfalls in available cleanroom space. The pandemic reshaped U.S. pharmaceutical manufacturing constructionowners.com: reshaped U.S. pharmaceutical manufacturing (outside source, not verified by ElevenFlo) and increased demand for domestic production capacity. The global cleanroom technologies market was valued at $8.3 billion in 2023 marketsandmarkets.com: valued at $8.3 billion in 2023 (outside source, not verified by ElevenFlo) and was projected to reach $12.3 billion by 2029, with pharmaceutical manufacturing at 42.2% of the market. The pharmaceutical regulatory affairs market served by Azzur's consulting arm was estimated at $9.47 billion in 2024 grandviewresearch.com: global pharmaceutical regulatory affairs market (outside source, not verified by ElevenFlo), with outsourcing at 59% of activity.
Cleanrooms on Demand offered a hybrid alternative to contract manufacturing ncbiotech.org: hybrid alternative to traditional contract manufacturing (outside source, not verified by ElevenFlo). Azzur provided turnkey GMP support: on-demand cleanroom space, materials management, storage, asset management and supply chain services. Clients kept control of their process, intellectual property and timeline. Modular cleanrooms were expected to be the fastest-growing part of the industry openpr.com: modular cleanroom segment (outside source, not verified by ElevenFlo), because pre-engineered systems cut construction time and cost. Moderna became an anchor client in one of Azzur's on-demand cleanroom facilities in 2021.
With Baird's capital, Azzur expanded its cleanroom footprint from one location in 2020 to facilities in North Carolina, Massachusetts and California by 2024. The Morrisville, North Carolina campus alone had 24 cleanrooms of 750 square feet each, which could be combined to meet client needs. When the pandemic subsided, the expected occupancy did not materialize. Revenue could not cover the fixed costs, which included about $280,000 a month in utilities and long-term leases at several sites Dkt. 12.
M&T's $62.2 million secured loan was most of the identified funded debt
The debtors borrowed under an April 7, 2020 Loan and Security Agreement with Manufacturers and Traders Trust Company (M&T). Azzur Group, LLC was lead borrower and each other debtor was a borrower. The agreement provided an asset-based revolving facility and a term loan facility, both secured by a first-priority lien on substantially all assets. The first-day declaration put the amount owed to M&T at about $62.2 million on the petition date, plus accrued interest, costs and fees Dkt. 12 · p. 8. That is the floor of identified funded debt: at least about $62.2 million, as stated in the filings. The DIP motion's stipulation gives $62,219,048.81 of principal as of February 28, 2025 Dkt. 11 · p. 176. The same declaration's capital structure chart lists February 28, 2025 as the maturity of both M&T facilities Dkt. 12 · p. 28.
Behind M&T were three unsecured promissory notes that Azzur Cleanrooms-on-Demand Devens, LLC and Azzur Group, LLC gave to contractors in July 2024. The notes settled mechanics' liens recorded against the leased premises. Their original principal amounts were $1,413,958 (Barker Note), $1,159,383 (Alameda Note) and $3,327,912 (Angstrom Note). About $5.2 million remained due on the three notes at the petition date Dkt. 12 · p. 9. The declaration also listed about $23.2 million of other general unsecured leasehold and trade obligations. It reported about $3.2 million of cash on hand, all of it M&T's cash collateral.
- M&T prepetition loan
- Contractor notes
- Loan Limit Line Advances (term loan)First lien$45.9M
- Line Advances (ABL revolver)First lien$13.0M
- Supplemental Line AdvancesFirst lien$2.0M
- Barker, Alameda and Angstrom notesUnsecured$5.2M
Show the numbers
| Obligation | Ranking | Amount |
|---|---|---|
| Loan Limit Line Advances (term loan) | First lien | $45.9M |
| Line Advances (ABL revolver) | First lien | $13.0M |
| Supplemental Line Advances | First lien | $2.0M |
| Barker, Alameda and Angstrom notes | Unsecured | $5.2M |
Source: DIP motion Dkt. 11 · p. 176; first-day declaration Dkt. 12 · p. 9
A year of forbearance produced one sale before the filing: Azzur Labs for $16 million
Liquidity pressure led to covenant breaches under the M&T loan in late 2023 Dkt. 12. The defaults were three: failure to meet the required fixed charge coverage ratio in the third quarter of 2023, failure to keep a $10 million minimum deposit, and a $3,750,000 out-of-formula advance on December 1, 2023. In December 2023, the company engaged DLA Piper LLP as counsel and Ankura Consulting Group as financial advisor. By January 2024, Brown Gibbons Lang had been retained as investment banker to pursue a capital stock sale or another transaction.
On February 26, 2024, Azzur entered a two-track forbearance agreement with M&T. Track 1 required raising up to $20 million by April 30, 2024, which would extend the loan maturity to November 1, 2025. If Track 1 failed, the maturity would spring forward to July 31, 2024. Track 2 required a sale or investment by July 31, 2024. The agreement was amended four times between August 2024 and January 2025 while marketing continued. Ankura Capital Advisors contacted 121 potential junior financing sources, and Brown Gibbons Lang contacted 63 potential structured equity investors. The effort produced 39 nondisclosure agreements and one preliminary indication of interest, which was not actionable.
In May 2024, M. Benjamin Jones, a Senior Managing Director at Ankura and Global Co-Head of its Turnaround & Restructuring practice, became Chief Restructuring Officer. A relaunched sale process contacted 47 more parties and produced 19 more nondisclosure agreements.
That process led to a letter of intent for Azzur Labs in November 2024. The sale closed on January 3, 2025 keystonecapital.com: closed on January 3, 2025 (outside source, not verified by ElevenFlo), when newly formed AL Holdings, Inc. bought the business for $16 million. All of the proceeds went to M&T: $12 million to the term loan, $2 million to the ABL facility and $2 million to outstanding line advances. Under the Fourth Amendment to the forbearance agreement, M&T also made a $2,000,000 Supplemental Line available to support liquidity while Azzur pursued the consulting sale Dkt. 736 · p. 83. The Labs business was rebranded as Gillson Testing and became part of Gillson Sciences, which runs GMP-compliant laboratories in Pennsylvania, Illinois and California.
M&T's $23.5 million DIP funded the sales and rolled up its prepetition loan
M&T, the prepetition lender, provided the DIP financing. The final DIP order, entered April 14, 2025, authorized up to $8.5 million of Supplemental DIP Line Advances and up to $15 million of other revolving advances, including letters of credit up to $1,335,507.66, for a $23.5 million aggregate limit Dkt. 414 · p. 14. The DIP motion described the $8.5 million as new money. It sought $11.75 million on an interim basis, made up of $4.25 million of term loans and $7.5 million of revolving loans Dkt. 11 · p. 126. Interest ran at the Base Rate plus 7.0%, with a default rate 3.0% higher. A $255,000 facility fee was due on the Ratification Effective Date.
The facility used a creeping roll-up. Prepetition obligations, stipulated at not less than $62,219,048.81 of principal, converted into DIP obligations dollar for dollar as collections repaid them after the interim order. Entry of the final order converted the rest, except a $1 million Remaining Pre-Petition Obligation Dkt. 414. The orders do not state the total amount converted. For adequate protection, M&T received replacement liens and a section 507(b) claim to the extent of any diminution in value. It also received payment of the fees of its counsel, Otterbourg P.C. and Richards, Layton & Finger, P.A.
An April 2, 2025 amendment to the interim order reset the consulting sale timeline. It set an April 9 auction, an April 11 sale hearing and an April 11 final financing hearing, and required a sale order by April 12 Dkt. 336. The debtors filed an amended DIP budget on April 11, 2025 Dkt. 392. The facility stayed in place until the plan's effective date, October 21, 2025.
The Devens landlord, King 45 Jackson LLC, filed a limited objection to the DIP motion on March 18, 2025. It said the debtors had not paid $516,173.99 of March stub rent included in the interim budget, that monthly rent and charges exceeded $530,000, and that the budget left out May rent Dkt. 117. The landlord also opposed the section 506(c) and 552(b) waivers and any liens on its leasehold. It had drawn more than $1.3 million on a letter of credit, and the debtors argued it was oversecured. Clarifying language was added to the final DIP order.
Eliquent's $56 million stalking-horse bid drew no rival, and the cleanroom unit sold for $600,000
Azzur filed chapter 11 with a stalking-horse agreement already signed: Eliquent Life Sciences, Inc. would buy Azzur Consulting for $56 million under section 363 prnewswire.com: sell its consulting business to Eliquent Life Sciences (outside source, not verified by ElevenFlo). Eliquent also agreed to assume certain liabilities. The bidding procedures order, entered March 28, 2025, approved a $1,680,000 break-up fee (3% of the cash price) and expense reimbursement of up to $1,000,000. It required a 10% deposit and overbids of at least the bid protections plus $200,000. It set an April 7 bid deadline, an April 9 auction and an April 11 sale hearing Dkt. 177. No competing qualified bid arrived. On April 8, 2025, the debtors cancelled the auction and named Eliquent the successful bidder at the stalking-horse price Dkt. 386. The court entered the sale order on April 14, 2025 Dkt. 408, and the sale closed on May 6, 2025 businesswire.com: Eliquent announcing the completed acquisition (outside source, not verified by ElevenFlo). The deal added commissioning, qualification and validation services; equipment and facility qualification; quality systems; IT compliance and computer systems validation; and GxP compliance consulting to Eliquent.
- Sold before the filing
- Sold in chapter 11
- Azzur LabsAL Holdings, Inc. · Jan. 3, 2025$16.0M
- Azzur ConsultingEliquent Life Sciences, Inc. · May 6, 2025$56.0M
- Cleanrooms on DemandChrysalis Holdings LLC · Apr. 30, 2025$0.6M
Show the numbers
| Business | Buyer | Closed | Price |
|---|---|---|---|
| Azzur Labs | AL Holdings, Inc. | Jan. 3, 2025 | $16.0M |
| Azzur Consulting | Eliquent Life Sciences, Inc. | May 6, 2025 | $56.0M |
| Cleanrooms on Demand | Chrysalis Holdings LLC | Apr. 30, 2025 | $0.6M |
Source: First Amended Combined Disclosure Statement and Plan Dkt. 531
Eliquent was formed in early 2024 eliquent.com: formed in early 2024 (outside source, not verified by ElevenFlo) by combining six consultancies: Validant, Greenleaf Health, DataRevive, Oriel Stat-a-Matrix, RApport Global and IDEC. It is backed by GHO Capital ghocapital.com: GHO Capital (outside source, not verified by ElevenFlo), a London-based specialist healthcare investment advisor. GHO has deployed over €4 billion across 26 platform companies since 2015 and has partnered with the Validant group since December 2018 ghocapital.com: partnered with the Validant group since December 2018 (outside source, not verified by ElevenFlo). Eliquent's CEO, Tim Dietlin, previously held life sciences leadership roles at IBM, INC Research and Campbell Alliance.
At filing, Azzur had about 342 employees (303 full-time and 39 part-time) and about 89 independent contractors Dkt. 12. About 250 employees and contractors moved to Eliquent with the consulting sale. They included Allison Kerska prnewswire.com: Allison Kerska (outside source, not verified by ElevenFlo), President of Azzur Consulting since April 2023 and earlier a senior executive at Kelly OCG and ManpowerGroup. By September 2025, all remaining employees of the debtors had been laid off.
The Cleanrooms on Demand business was sold separately. The court approved that sale by an order signed April 25, 2025 and filed under seal Dkt. 477. Chrysalis Holdings LLC paid $600,000 plus assumed liabilities Dkt. 531, and the sale closed on April 30, 2025. The same day, the debtors rejected the leases for five remaining locations: Waltham, Burlington and Devens, Massachusetts; Morrisville, North Carolina; and the Hatboro, Pennsylvania headquarters.
Editas Medicine, Inc. licensed space at the Devens facility under a License and Services Agreement. Azzur claimed about $8.1 million in license fees through Editas's July 31, 2026 early termination date; the monthly license fee alone exceeded $500,000. Editas disputed the calculation, citing pro rata fees and offsets. On April 14, 2025, the court approved a settlement under which Editas agreed to pay $3.7 million in cash in full satisfaction. Payment depended on Azzur vacating Devens by April 30, 2025, and a $30,000 daily holdover penalty applied after that date Dkt. 465. The confirmation order lists the Editas settlement among the sources of plan distributions Dkt. 736.
Confirmation failed in May 2025 and succeeded in October after insiders added $790,000
The debtors filed a combined disclosure statement and liquidating plan on March 7, 2025 Dkt. 85. It provided for going-concern sales followed by a wind-down run by a Plan Administrator, with Azzur Group, LLC as the wind-down debtor. A revised version followed on April 10 Dkt. 386 and a solicitation version on April 14 Dkt. 410. Those versions projected about 71% for M&T's Class 3 claim of about $51.2 million. They projected less than 1% for Class 4 general unsecured claims of about $45.8 million, with the unsecured recovery capped at $200,000.
The First Amended plan, filed May 12, 2025, added a settlement among the debtors, the Committee and M&T Dkt. 531. M&T agreed to fund a $1.625 million Class 4 Settlement Amount, including $500,000 for Committee professional fees. It also agreed to take no recovery from that fund on its deficiency claim. The plan then projected about 63% for M&T and about 2.1% for Class 4, an estimated general unsecured recovery of $625,000.
The court denied confirmation after a hearing on May 19–20, 2025. It sustained objections from the U.S. Trustee and the Committee on three points: the carve-outs for gross negligence, willful misconduct and fraud in the debtor release; the exculpation provision as drafted; and, on the Committee's objection, the debtors' choice of Plan Administrator. Months of negotiation followed. By September 2025, the U.S. Trustee had moved to compel the debtors to file an amended plan, noting that all employees had been laid off. That motion restarted talks among the debtors, the Committee, M&T and the insiders covered by the releases.
The talks produced a Global Settlement, described in a supplemental declaration by the CRO Dkt. 732. Its parties were the debtors, the Committee, M&T, the estates' retained professionals and 14 Settling Released Parties. Those parties were company insiders Michael Khavinson, Gary Knight, Ryan Ott (COO), Ilya Vasserman (CIO), Joe Perrotto, Rob Ospalik, John Riddle, Brett Tucker, David Schroeder and CRO M. Benjamin Jones, plus equity holders Yotomachi LLC, Azzur Blocker LLC, G. Knight Consulting Ltd. and BGL Azzur LLC. The Settling Released Parties agreed to contribute $790,000 in cash for Class 4. Adding the $1.625 million Class 4 Settlement Amount, the declaration put Class 4 funding at $2.415 million. A December 22, 2021 promissory note between Gary Knight and Azzur Group Holdings was deemed abandoned.
The court confirmed the plan on October 3, 2025 Dkt. 736. Appointing Maria Yip resolved the Committee's objection to the Plan Administrator. The third-party release became consensual through opt-in and opt-out mechanics, and exculpation no longer reaches the prepetition period. Class 4 accepted by 98.0% to 99.9% in amount and 88.2% in number. The plan became effective on October 21, 2025 Dkt. 743, about seven and a half months after the petition date.
Every cause of action that the plan does not release vests in the wind-down debtor, including chapter 5 claims. M&T keeps liens on the proceeds of certain retained actions, but not on chapter 5 or insider claims Dkt. 735. Contracts and leases that had not been assumed were rejected on the effective date. Insurance policies, including the Chubb program, pass to the wind-down debtor unaltered. Administrative claims and final fee applications were due 30 days after the effective date.
The confirmed plan projects about 63% for M&T and 2.1% plus settlement cash for unsecured creditors
| Class | Claims | Estimated claims | Estimated recovery |
|---|---|---|---|
| 1 | Other secured claims | about $1.3 million | 100% |
| 2 | Other priority claims | De minimis | 100% |
| 3 | M&T claims | about $51.2 million | about 63% (71% in the April plan) |
| 4 | General unsecured claims | about $30.1 million | about 2.1%, plus Global Settlement funds |
| 5 | Intercompany claims | Not applicable | No distribution |
| 6A/6B | Equity interests and section 510(b) claims | Not applicable | 0% |
The confirmation order shows Class 4 at about 2.1% plus settlement funds Dkt. 736. The 2.1% figure dates from the May plan and does not include the $790,000 added later. Earlier versions of the plan had projected less than 1%. M&T's secured claim was paid from the proceeds of the consulting and cleanroom sales. The latest post-confirmation report still shows no payment on general unsecured claims Dkt. 968.
Two claim fights outlasted confirmation: L.E.A.F. is limited to insurance, and Eliquent sought deposits and an administrative claim
L.E.A.F. Pharmaceuticals LLC moved for relief from stay over a prepetition dispute Dkt. 424. It alleged that Azzur destroyed or lost active pharmaceutical ingredients for a patented cancer drug stored at an Azzur facility under a Master Services Agreement. It sought at least $2 million in replacement costs and $18.75 million in lost profits. The confirmation order lifted the stay only to let L.E.A.F. contest insurance coverage denials and, if it succeeds, liquidate its claim in state court. Any recovery is limited to insurance proceeds, and the claim is disallowed against the estates as of the effective date Dkt. 736.
In November 2025, Eliquent moved to enforce the sale order Dkt. 762. It sought turnover of $284,644.81 in customer deposits and allowance and immediate payment of a $129,529.48 administrative claim for transition services.
The U.S. Trustee and the Committee contested the banker's retention and the insider incentive plan
The debtors retained DLA Piper LLP as lead counsel, Ankura Consulting Group as financial advisor and CRO provider, and Brown Gibbons Lang & Company as investment banker. Stretto, Inc. served as claims and noticing agent. The U.S. Trustee objected to BGL's retention, arguing that a BGL managing director's prior board service meant the firm was not a disinterested person. The debtors answered with declarations on recusal procedures, ethical walls and waivers of claims, and the court approved the retention. Pachulski Stang Ziehl & Jones LLP represented the Official Committee of Unsecured Creditors, with Huron Consulting Services as its financial advisor.
The debtors also proposed a Sale Incentive Plan for five participants: Khavinson (CEO), Ott (COO), Vasserman (CIO), Kalinovich (CFO) and Knight (independent manager). It would have cost $1,575,000 at the stalking-horse price. The Committee and the U.S. Trustee objected. The Committee argued that the program was a disguised retention plan rather than a true incentive plan. It also challenged Knight's inclusion: as an independent director he would have received about $300,000, about 21% of the total and roughly three times his annual compensation.
Sources
- Dkt. 1Chapter 11 Voluntary Petition . Fee Amount $1738. Filed by Azzur Group Holdings LLC. (Brown, Stuart)Filed Mar 2, 2025Mar 2, 2025
- Dkt. 11DIP Financing MotionFiled Mar 3, 2025Mar 3, 2025
- Dkt. 12First Day Declaration of CROFiled Mar 3, 2025Mar 3, 2025
- Dkt. 85Combined Disclosure Statement and Liquidation PlanFiled Mar 7, 2025Mar 7, 2025
- Dkt. 117Limited Objection to DIP MotionFiled Mar 18, 2025Mar 18, 2025
- Dkt. 177Azzur Group Bidding Procedures OrderFiled Mar 28, 2025Mar 28, 2025
- Dkt. 336Order (First Amendment to Interim) (I) Authorizing Debtors and Debtors in Possession to (A) Obtain Postpetition Financing, (B) Grant Liens and Super-Priority Claims, and (C) Grant Adequate Protection; (II) Modifying the Automatic Stay; (III) Scheduling a Final Hearing; and (IV) Granting Related Relief (related document(s)[11], [19], [63], [331]) Order Signed on 4/2/2025. (Mml)Filed Apr 2, 2025Apr 2, 2025
- Dkt. 386Combined Plan and Disclosure StatementFiled Apr 10, 2025Apr 10, 2025
- Dkt. 392Exhibit(s) / Notice of Filing Amended Debtor in Possession Financing Budget (related document(s)[11]) Filed by Azzur Group Holdings LLC. (Attachments: # (1) Exhibit A) (Brown, Stuart)Filed Apr 11, 2025Apr 11, 2025
- Dkt. 408(Redacted) Order (I) Approving and Authorizing the Sale of the Debtors' Consulting Business and Related Assets, (II) Approving Assumption and Assignment of Certain Executory Contracts, and (III) Granting Related Relief (related document(s)[13], [177], [360], [384], [405]) Order Signed on 4/14/2025. (Attachments: # (1) Exhibit 1 # (2) Exhibit 2) (Mml)Filed Apr 14, 2025Apr 14, 2025
- Dkt. 410Combined Chapter 11 Plan and Disclosure StatementFiled Apr 14, 2025Apr 14, 2025
- Dkt. 414Order (Final) (I) Authorizing Debtors and Debtors in Possession to (A) Obtain Postpetition Financing, (B) Grant Liens and Super-Priority Claims, and (C) Grant Adequate Protection; (II) Modifying the Automatic Stay; and (III) Granting Related Relief (Related Doc # [11], [19], [63], [336], [385], [392] [406]) Order Signed on 4/14/2025. (Attachments: # (1) Exhibit A # (2) Exhibit B) (Mml)Cited at p. 14 · Filed Apr 14, 2025Apr 14, 2025
- Dkt. 424Motion for Relief from StayFiled Apr 16, 2025Apr 16, 2025
- Dkt. 465Order Approving the Editas Settlement and the Debtors' Entry Into and Performance Under the Settlement Agreement By and Among Azzur Cleanrooms-on-Demand - Devens, LLC and Editas Medicine, Inc. (Related Doc # [412], [460]) Order Signed on 4/22/2025. (Attachments: # (1) Exhibit 1) (Mml)Filed Apr 22, 2025Apr 22, 2025
- Dkt. 477[SEALED] Order (I) Approving and Authorizing the Sale of the Debtors' Cleanrooms-On-Demand Business and Related Assets, (II) Approving Assumption and Assignment of Certain Unexpired Leases and Executory Contracts, and (III) Granting Related Relief (related document(s)[13], [42], [91], [131], [138], [177], [363], [419], [434], [439], [441], [442], [457], [459], [473]) Order Signed on 4/25/2025. (Attachments: # (1) Exhibit 1 # (2) Exhibit 2 # (3) Exhibit 3) (Mml)Filed Apr 25, 2025Apr 25, 2025
- Dkt. 531Amended Combined Plan and Disclosure StatementFiled May 12, 2025May 12, 2025
- Dkt. 732Supplemental Declaration Supporting Global SettlementFiled Oct 2, 2025Oct 2, 2025
- Dkt. 735Order Confirming Combined Disclosure Statement and PlanFiled Oct 3, 2025Oct 3, 2025
- Dkt. 736Plan Confirmation OrderCited at p. 83 · Filed Oct 3, 2025Oct 3, 2025
- Dkt. 743Exhibit(s) / Notice of (I) Entry of Findings of Fact, Conclusions of Law, and Order Confirming First Amended Combined Disclosure Statement and Joint Chapter 11 Plan of Azzur Group Holdings LLC and Its Affiliated Debtors and (II) Occurrance of Effective Date (related document(s)[735]) Filed by Azzur Group Holdings LLC. (Brown, Stuart)Filed Oct 21, 2025Oct 21, 2025
- Dkt. 753DLA Piper Final Fee RequestFiled Nov 12, 2025Nov 12, 2025
- Dkt. 762Eliquent Motion to Enforce Sale and Pay Admin ClaimsFiled Nov 20, 2025Nov 20, 2025
- Dkt. 770PSZ&J Final Compensation OrderFiled Dec 15, 2025Dec 15, 2025
- Dkt. 771Omnibus Final Fee Approval OrderFiled Dec 15, 2025Dec 15, 2025
- Dkt. 772Order Granting Huron Final Fee ApplicationFiled Dec 15, 2025Dec 15, 2025
- Dkt. 954Monthly Operating Report: Azzur Labs-BostonFiled Jul 8, 2026Jul 8, 2026
- Dkt. 960Rescheduled U.S. Trustee HearingFiled Aug 11, 2026Aug 11, 2026
- Dkt. 962Quarterly Post-Confirmation ReportFiled Sep 4, 2026Sep 4, 2026
- Dkt. 963Rescheduled U.S. Trustee HearingFiled Sep 17, 2026Sep 17, 2026
- Dkt. 966Quarterly Post-Confirmation ReportFiled Oct 14, 2026Oct 14, 2026
- Dkt. 967Quarterly Post-Confirmation ReportFiled Oct 14, 2026Oct 14, 2026
- Dkt. 968Quarterly Post-Confirmation ReportFiled Oct 21, 2026Oct 21, 2026
- Dkt. 969Trustee Withdraws MotionFiled Oct 22, 2026Oct 22, 2026
- WebHatboro, Pennsylvaniaglensidelocal.com · Outside source, not verified by ElevenFlo
- WebAzzur Group announced an investment from Baird Capitalprnewswire.com · Outside source, not verified by ElevenFlo
- Webexpertise in pharma servicesbairdcapital.com · Outside source, not verified by ElevenFlo
- Webpushed testing, diagnostics, and manufacturing capabilities toward capacitypharmaceuticalmanufacturer.media · Outside source, not verified by ElevenFlo
- Webreshaped U.S. pharmaceutical manufacturingconstructionowners.com · Outside source, not verified by ElevenFlo
- Webvalued at $8.3 billion in 2023marketsandmarkets.com · Outside source, not verified by ElevenFlo
- Webglobal pharmaceutical regulatory affairs marketgrandviewresearch.com · Outside source, not verified by ElevenFlo
- Webhybrid alternative to traditional contract manufacturingncbiotech.org · Outside source, not verified by ElevenFlo
- Webmodular cleanroom segmentopenpr.com · Outside source, not verified by ElevenFlo
- Webclosed on January 3, 2025keystonecapital.com · Outside source, not verified by ElevenFlo
- Websell its consulting business to Eliquent Life Sciencesprnewswire.com · Outside source, not verified by ElevenFlo
- WebEliquent announcing the completed acquisitionbusinesswire.com · Outside source, not verified by ElevenFlo
- Webformed in early 2024eliquent.com · Outside source, not verified by ElevenFlo
- WebGHO Capitalghocapital.com · Outside source, not verified by ElevenFlo
- Webpartnered with the Validant group since December 2018ghocapital.com · Outside source, not verified by ElevenFlo
- WebAllison Kerskaprnewswire.com · Outside source, not verified by ElevenFlo